Diabetic Kidney Disease and Clinical Research on Autologous Urine-Derived Mesenchymal Stem Cells: What to Consider Before Participating

For people who have been managing diabetes for many years, kidney function testing is an important health indicator alongside blood glucose levels. Diabetic kidney disease is a condition in which diabetes damages the small blood vessels in the kidneys and impairs their filtration function, and noticeable symptoms may not appear in the early stages. EHL Cell Clinic is recruiting participants for an advanced regenerative medicine clinical study evaluating the safety and efficacy of autologous urine-derived mesenchymal stem cells in patients with diabetic kidney disease.

This recruitment does not involve a treatment whose efficacy has already been established. It is a clinical study that follows a defined research protocol to assess the safety of the investigational approach and whether its efficacy can be evaluated when stem cells derived from a participant’s own cells are administered. Those considering participation should make an informed decision after receiving a full explanation of the study’s purpose, anticipated procedures, potential burdens, and the right to withdraw.

Why Does Diabetic Kidney Disease Require Management Even Without Symptoms?

The kidneys filter waste products and excess fluid from the blood and excrete them through urine and help maintain the body’s fluid and electrolyte balance. Prolonged exposure to high blood glucose levels can damage the kidneys’ microvasculature, potentially causing protein to leak into the urine and kidney function to gradually decline.

The progression of diabetic kidney disease can vary from person to person. By the time symptoms such as swelling or fatigue become noticeable, changes in kidney function may already have progressed. For this reason, it is important to monitor the condition through regular urine and blood tests. Healthcare professionals assess kidney health by considering blood glucose, blood pressure, urine protein-related markers, and estimated glomerular filtration rate together.

Estimated glomerular filtration rate, or eGFR, is an indicator used to estimate how effectively the kidneys filter blood. The consultation criteria for this clinical study include an eGFR of 15–59 mL/min/1.73 m². However, participation is not determined by this value alone; overall health status, test results, and the inclusion and exclusion criteria established for the study are also reviewed.

What Are Autologous Urine-Derived Mesenchymal Stem Cells?

Autologous urine-derived mesenchymal stem cells are mesenchymal stem cells isolated and cultured from cells obtained from a participant’s own urine. Here, “autologous” means that the participant’s own cells, rather than cells from another person, are used. Mesenchymal stem cells are a type of cell studied in various tissues, and regenerative medicine research continues to explore their potential in relation to tissue injury and inflammatory responses.

Understanding the source of the cells and the purpose of the research is important, but the name or type of a cell alone does not establish clinical efficacy or safety. The processes used to isolate and culture cells, the method of administration, the participant’s underlying conditions and overall health status, and the study design can all affect the interpretation of results. For this reason, clinical studies involving human participants evaluate safety and efficacy according to established criteria.

EHL BIO’s internal materials describe cell therapy research involving urine-derived stem cells for chronic kidney disease, as well as research related to Klotho protein secretion. However, research and development materials should be distinguished from the results of a specific clinical study, and participation in the currently recruiting study does not guarantee any specific treatment outcome.

How Does an Advanced Regenerative Medicine Clinical Study Differ from an Approved Treatment?

An advanced regenerative medicine clinical study is conducted to evaluate safety, efficacy, and other factors when advanced regenerative medicine technologies are applied, such as cells and genes, in humans. Studies are conducted under procedures designed to protect participants’ rights and safety, and participation is determined only after the study’s purpose and methods have been fully explained and voluntary consent has been obtained.

Approved routine care and standard treatments are provided in accordance with regulatory authorizations and clinical practice guidelines. By contrast, a clinical study is a process used to evaluate medical technologies that remain at the research stage. Therefore, not only potential benefits but also uncertainties and other relevant considerations should also be carefully reviewed. Participants may ask the research team specific questions about the study’s purpose, visit schedule, tests, potential discomfort and risks, and cost-related matters.

The informed consent form is an important part of study participation, but signing it does not guarantee a therapeutic effect. Participants may decide not to participate after receiving sufficient information, and may withdraw from the study at any time, even after providing consent. It is also important to understand in advance that participation may be restricted depending on one’s health status.

Who Is Eligible for Consultation, and What Does the Process Involve?

According to the provided information, consultation is available to adults aged 19 or older and under 80 who have been diagnosed with diabetic kidney disease. Individuals with an eGFR within the range of 15–59 mL/min/1.73 m² who are willing to provide voluntary consent after receiving a full explanation of the clinical study may be eligible for consultation.

Even if an individual meets the consultation criteria, this does not automatically confirm eligibility for participation. The research team reviews health status, test results, and detailed inclusion and exclusion criteria to determine eligibility. During the consultation, it is advisable to accurately disclose any medications currently being taken, their history of diabetes and kidney disease management, and any other existing medical conditions.

When considering study participation, it may also be helpful to review one’s current kidney management plan with a primary physician beforehand. Regardless of whether one participates in the clinical study, existing care—including blood glucose and blood pressure management, prescribed medications, and regular testing—should not be discontinued or modified without medical guidance. Individual test results and treatment decisions should be interpreted and made in consultation with healthcare professionals.

Inquiries regarding this study are handled by EHL Cell Clinic, and the inquiry telephone number is 02-532-9880. The research institution is located at EHL Building, 136 Apgujeong-ro, Gangnam-gu, Seoul. Receiving a consultation does not guarantee participation in the study, and individuals may take sufficient time to consider their decision after receiving the relevant information.

Questions to Consider When Deciding Whether to Participate

In diabetic kidney disease, it is important to distinguish between routine health management and participation in clinical research. A clinical study is a scientific process for exploring future treatment options, but for participants, it is also a personal decision that requires consideration of their current health status, daily circumstances, and the uncertainties involved in the research.

EHL BIO focuses on stem cell-based regenerative medicine research, and progress in this field should be assessed through long-term validation and transparent disclosure of information. For those considering participation, the most important considerations go beyond expectations alone, but also the stage of the research, their individual suitability, and voluntary, informed consent.

About EHL BIO

EHL BIO is a biotechnology company focused on advancing human health through stem cell-based regenerative medicine. By scientifically exploring the innate self-repair and regenerative capabilities of cells, it is developing new approaches to aging and disease. By combining premium healthcare with advanced biotechnology, EHL BIO provides solutions for healthier, more vital lives.